The emerging role of phosphate in vascular calcification  by Giachelli, Cecilia M.
The emerging role of phosphate in vascular
calcification
Cecilia M. Giachelli1
1Department of Bioengineering, University of Washington, Seattle, Washington, USA
Vascular calcification is recognized as a major contributor to
cardiovascular disease (CVD) in end stage renal disease
(ESRD) patients. Susceptibility to vascular calcification is
genetically determined and actively regulated by diverse
inducers and inhibitors. One of these inducers,
hyperphosphatemia, promotes vascular calcification and is a
nontraditional risk factor for CVD mortality in ESRD patients.
Vascular smooth muscle cells (SMCs) respond to elevated
phosphate levels by undergoing an osteochondrogenic
phenotype change and mineralizing their extracellular matrix
through a mechanism requiring sodium-dependent
phosphate cotransporters. Disease states and cytokines can
increase expression of sodium-dependent phosphate
cotransporters in SMCs, thereby increasing susceptibility to
calcification even at phosphate concentrations that are in the
normal range.
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DEFINITIONS AND CLINICAL SIGNIFICANCE OF VASCULAR
CALCIFICATION
Calcification of the cardiovascular system is associated with a
number of diseases including end stage renal disease (ESRD)
and cardiovascular disease (CVD). Calcium phosphate
deposition, mostly in the form of apatite, is the hallmark of
vascular calcification and can occur in the blood vessels,
myocardium and cardiac valves.1 Calcium phosphate depos-
its are found in distinct layers of the blood vessel and are
associated with specific pathologies. Intimal calcification is
observed in atherosclerotic lesions,2,3 whereas medial calci-
fication is common to the arteriosclerosis observed with age
and diabetes, and is the major form observed in ESRD.4–6 In
ESRD patients, both intimal and medial calcification occurs,
but arterial medial calcification is by far the most
prevalent.7,8 Levels of calcium on the order of 20 mg/mg
were routinely found in the calcified aortas of uremic patients
at autopsy.7 In valves, calcification is a defining feature of
aortic valve stenosis, and occurs in both the leaflets and ring,
predominantly at sites of inflammation and mechanical
stress.9
Some pathological states of vascular calcification are well
recognized for their life threatening potential. For example,
calcification is recognized as a major mode of failure of native
and bioprosthetic valves.10,11 Furthermore, vascular calcifica-
tion is responsible for calcific uremic arteriolopathy, a
necrotizing skin condition observed in dialysis patients,
associated with extremely high mortality rates.12 Finally,
generalized infantile arterial calcification, a genetic disease
characterized by deficiencies in ENPP1, the enzyme that
generates the potent inhibitor of calcium phosphate deposi-
tion, pyrophosphate, causes arterial calcification, fibrosis, and
stenosis, which leads to premature death in afflicted
neonates.13
In contrast, vascular calcifications associated with age,
renal and vascular disease were considered benign for the
better part of the last century. However, clinical studies in the
past two decades have challenged this dogma. Calcification
has been positively correlated with coronary atherosclerotic
plaque burden14,15 increased risk of myocardial infarc-
tion16–18 and plaque instability.19–21 Furthermore, in the
Rotterdam Coronary Calcification Study, a large population-
based study, graded associations between coronary calcifica-
tion score and stroke were identified.22 Likewise, coronary
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calcium score was a strong predictor of incident coronary
heart disease in four major racial and ethnic groups in the
United States.23 Similarly, medial arterial calcification is
strongly correlated with coronary artery disease and future
cardiovascular events including lower extremity amputation
in type I diabetics24,25 and is a strong prognostic marker of
CVD mortality in ESRD patients.26 These findings may be
explained by evidence that arterial medial calcification in
large arteries leads to increased stiffness and therefore
decreased compliance of these vessels. These mechanical
changes are associated with increased arterial pulse wave
velocity and pulse pressure, and lead to impaired arterial
distensibility, increased afterload favoring left ventricular
hypertrophy, and compromised coronary perfusion.27 Thus,
both intimal and medial calcifications may contribute to the
morbidity and mortality associated with cardiovascular
disease, and are likely to be major contributors to the
10–100 fold increase in cardiovascular mortality risk observed
in ESRD patients.28 Indeed, both the National Kidney
Foundation and American Heart Association have indicated
that ESRD patients should be considered at the highest risk
for cardiovascular disease (NFK K/DOQI clinical guidelines
and Sarnak et al.29).
VASCULAR CALCIFICATION IS AN ACTIVELY REGULATED,
GENETICALLY DETERMINED PROCESS
Growing evidence suggests that vascular calcification, like
bone formation, is a highly regulated process, involving both
inductive and inhibitory processes (El-Abbadi and Giachelli30
for review). For example, apatite, bone-related noncollagen-
ous proteins (osteocalcin, osteopontin, alkaline phosphatase,
Runx2), and matrix vesicles have all been observed in
calcified vascular lesions. Furthermore, outright cartilage and
bone formation have also been documented.2,9,31 Finally, cells
derived from the arterial media, including smooth muscle
cells (SMCs), adventitial fibroblasts, and pericytes, undergo
osteochondrogenic differentiation and matrix mineralization
under the appropriate conditions in vitro.32–36 These studies
suggest that cell-mediated processes tightly control procalcific
and anticalcific mediators in the artery so that ectopic
calcification is normally avoided. Under pathological
conditions, this balance is upset and leads to ectopic
mineralization.
Furthermore, susceptibility to vascular calcification ap-
pears to be genetically determined in people and in mice. For
example, Table 1 lists human genetic syndromes and mouse
mutations that include vascular calcification as part of the
disorder, indicating that the affected genes normally regulate
this process. Furthermore, a small fraction of ESRD patients
enter dialysis without vascular calcification and remain
calcification-free suggesting genetic protection against this
process.37 More recently, ESRD patients with ENPP1 121KQ
genotype (decreased pyrophosphate-generating capacity)
were found to have significantly higher coronary calcium
score and pulse pressure than ENPP1 121KK genotype.38
Likewise, using inbred and BH recombinant inbred mouse
strains, clear differences in the occurrence of coronary arterial
medial calcification in response to an atherogenic diet was
observed, with the most susceptible strains being DBA/2J and
C3H/HeJ, whereas the least susceptible included C57Bl/6 and
MRL/lpr.39 Interestingly, susceptibility to atherosclerotic
plaque formation and cartilaginous metaplasia, especially in
ApoE-deficient mice, appeared to show the reverse trend,
with C57Bl/6 showing much greater lesion formation and
ectopic cartilage than C3H mice.39–41 Furthermore, dys-
trophic cardiac calcification (DCC), an autosomal recessive
complex trait characterized by calcium phosphate deposition
in the myocardium following various injurious stimuli, is
preferentially induced in the DCC susceptible C3H/HeJ and
DBA/2J strains compared with DCC-resistant C57Bl/6
strain.42,43 Indeed, recent studies have identified a quantita-
tive trait locus (Dyscalc 1) contributing to the DCC
phenotype to encode the ATP-binding cassette transporter,
ABCC6.44 Mutations in this gene in people are
responsible for pseudoxanthoma elasticum (Table 1), a
condition that includes enhanced vascular calcifications.45
Of note, the substrate for ABCC6, which is expressed in liver,
kidney and heart but not blood vessels, has not yet been
identified.
Thus, over the past 10 years, our understanding of
molecules and processes that regulate ectopic calcification
has grown exponentially. As mentioned, much of our
understanding comes from the identification of genes
through linkage or targeted deletion studies that cause
human and/or mouse ectopic calcification disorders, respec-
tively. In addition, a number of in vitro and in vivo model
systems have been developed that mimic important aspects of
ectopic calcification. Figure 1 summarizes the current major
theories and regulators of vascular calcification that have
been put forward based on these studies including failed
anticalcific mediators, (2) induction of osteochondrogenesis,
(3) apoptosis, (4) abnormal calcium and phosphate
homeostasis, (5) circulating nucleational complexes/
paracrine factors derived from bone and (6) matrix
degradation. However, the key factors and processes
important for any specific disease state are still unknown,
and it is likely that a different set of processes/molecules
may uniquely be involved in different pathologies. In this
regard, serum phosphate and cellular phosphate metabolism
are emerging as key regulators of vascular calcification in
ESRD.
As shown in Figure 1, phosphate may contribute
to multiple mechanisms that initiate and/or promote
progression of vascular calcification. Although this
review focuses on the role of phosphate in promoting
osteochondrogenic conversion of vascular cells (mechanism
2), some evidence suggests that elevated phosphate
may also contribute to vascular calcification by promoting
apoptosis46 as well as raising the calcium phosphate
product (Ca P) thereby thermodynamically favoring
crystal formation.47 In addition, Massy et al.48 and others
have suggested that elevated phosphate might also contribute
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to vascular calcification by inhibiting osteoclastic differentia-
tion,48–51 though further evidence for this in the context of
vessel wall calcification is needed. Whether elevated
phosphate contributes to loss of anticalcific molecules, such
as decreased fetuin levels in ESRD patients, circulating
nucleational complexes or matrix degradation is not yet
known.
HYPERPHOSPHATEMIA, ELEVATED PHOSPHATE LOAD, AND
VASCULAR CALCIFICATION
Evidence for the importance of hyperphosphatemia as a
major inducer of vascular calcification comes from studies of
genetic syndromes (Table 1) as well as diseases of renal
insufficiency. Hyperphosphatemia is observed in two human
genetic disorders that cause familial tumoral calcinosis due to
mutations in the genes for FGF23, a major phosphaturic
hormone, and UDP N-acetyl-a-D-galactosamine.52,53 Like-
wise, in mice, targeted deletion of either FGF2354,55 or klotho,
an aging-suppressor gene required for FGF23 function,56
leads to hyperphosphatemia that is accompanied by vascular
calcification.
Hyperphosphatemia is also prevalent in patients with
ESRD. Evidence from observational studies reveals that
elevated serum phosphate is positively correlated with
mortality, and an increase in risk of death is observed
in ESRD patients with a serum phosphate greater than
Table 1 | Genes associated with vascular calcification in mice and men
Gene Mouse mutant phenotypea Human genetic mutation/phenotype
Matrix Gla protein Arterial, valve, and cartilage calcification (Luo, 1997) Keutel syndrome/cartilage and soft tissue calcification
(Hur, 2005)
Fetuin Low serum HA inhibitory activity; enhanced
susceptibility to vitamin D overload-induced
vascular calcification (Schafer, 2003)
None reported
Osteopontin Increased calcification of implanted bioprosthetic valve
tissue (Steitz, 2002; Ohri, 2005); increased vascular
calcification in OPN/XMGP/ mice (Speer, 2002)
None reported
Osteoprotegerin Vascular calcification and osteoporosis (Bucay, 1998) None reported
FGF23 Hyperphosphatemia; high serum vitamin D; vascular
calcification (Stubbs, 2007)
Familial tumoral calcinosis/vascular calcification,
hyperphosphatemia, high-serum vitamin D (Benet
Pages, 2005)
Klotho (b-glucuronidase) Vascular calcification, rapid aging (Kuro-o, 1997) Tumoral calcinosis, hyperphosphatemia (Ichikawa, 2007)
Nucleotide pyrophosphatase)
Enpp1/PC-1/NPP1
Tip-toe walking mouse/vascular and articular cartilage
calcification (Okawa, 1998)
Infantile arterial calcification/low pyrophosphate,
extensive vascular calcification, neonatal lethal
(Rutsch, 2003)
Ank (pyrophosphate
transporter)
Progressive ankylosis; articular cartilage calcification;
soft tissue calcification (Harmey, 2004)
Calcium pyrophosphate deposition disease/
chondrocalcinosis; high pyrophosphate (Zaka, 2006)
Carbonic anhydrase II Small artery VC; osteopetrosis; metabolic acidosis
(Spicer, 1989)
Osteopetrosis, metabolic acidosis, brain calcifications
(Shah, 2004)
Smad 6/Madh6 Endocardial cushion defects; valvular calcification
(Galvin, 2000)
None reported
Desmin Neonatal cardiomyopathy with calcification
(Mavroidis, 2002)
None reported
UDP N-acetyl-a-D-
galactosamine
(GalNT3)
None reported Familial tumoral calcinosis/hyperphosphatemia, vascular
calcification, elevated serum vitamin D (Ichikawa, 2005)
Fibrillin 1 Marfan-like syndrome, elastocalcinosis and aneurysm Marfan syndrome
Fibulin 4 Valve calcification and stenosis, aortic dilatation Cutis laxa, aortic aneurysm, perinatal lethal (Dasouki, 2007)
ABCC6 transporter
(substrate unknown)
Extensive soft tissue and vibrissae calcification
(Klement, 2005)
Pseudoxanthoma elasticum/calcification of skin, connective
tissue and vasculature (Le Saux, 2000)
BMP and receptor BMP4 overexpressing transgenic: fibrodysplasia
ossificans-like phenotype (Kan, 2004)
ACVR1 BMP receptor, activating mutations: fibrodysplasia
ossificans progressiva/muscle/soft tissue calcification
(Shore, 2006)
WRN RecQ helicase Accelerated mortality in p53 null background
(Lombard, 2000)
Werner’s syndrome/soft tissue calcification (Uhrhammer,
2006)
Lamin A (LMNA) Cardiac and skeletal myopathy; progressive loss of
vascular SMC and calcification (Varga, 2006)
Hutchinson–Gilford progeria/calcification associated with
atherosclerosis (Eriksson, 2003)
Glucocerebrosidase
(D409H)
Lysosomal storage disorder, valve calcification
not found (Xu, 2003)
Gaucher disease/lysosomal storage disease; valvular and
aortic arch calcification (McMahon, 2001)
Transcription
intermediatery
factor 1 (TIF1a)
Ectopic calcification, including arterioles and
medium-sized arteries (Ignat, 2008)
None reported
Calcium sensing
receptor (CaSR)
Gprc2aNuf mouse, activating mutation: ectopic
calcification including arterial calcification and
cataracts (Hough, 2004)
Activating mutations: autosomal-dominant hypocalcemia,
hypercalciuria, and Bartter-like syndrome (Pollak, 1994)
Abbreviations: ABCC6, ATP-binding cassette transporter 6; BMP, bone morphogenetic protein.
aLoss of function mutation is shown unless otherwise stated.
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6.5 mg/dl.57 Despite one negative trial,58 the weight of clinical
evidence from three recent randomized clinical trials showed
that lowering serum phosphate levels with a non-calcium
containing phosphate binder slows progression of vascular
calcification in ESRD patients.59–61 Moreover, even relatively
small elevations in serum phosphate in the high normal
range (3.5–4.5 mg/dl) have been correlated with increased
risk of cardiovascular and all-cause mortality in both
chronic kidney disease patients62 and the general popula-
tion.63 Thus phosphate load, even in the absence of outright
hyperphosphatemia, may be an important driver of vascular
calcification.
Experimental models of renal insufficiency also point to a
role of elevated phosphate in vascular calcification. Uremic
rats show aortic medial calcification with prolonged (6
months) feeding of a high phosphate diet that could be
blocked by treatment with the phosphate binder, sevelamer.64
Hyperphosphatemia has also been correlated with athero-
sclerotic calcification in uremic, high fat fed LDLR null
mice,65 and sevelamer decreased vascular calcification in this
setting. Similarly, Massy et al.66 showed that uremia
accelerated atherosclerosis and vascular calcification in
ApoE/ mice and sevelamer-prevented uremia enhanced
atherosclerotic lesion size as well as calcification in this
model. Finally, hyperphosphatemia was correlated with
extensive arterial medial calcification similar in type and
extent to that observed in ESRD patients in the calcification-
prone DBA/2 mouse in response to severe renal insufficiency
and high phosphate feeding (CM Giachelli et al., unpublished
observations).
POTENTIAL ROLE OF THE SODIUM-DEPENDENT PHOSPHATE
COTRANSPORTER, PIT-1, IN VASCULAR CALCIFICATION
Consistent with clinical and animal studies, phosphate levels
comparable to those seen in hyperphosphatemic individuals57
induce SMC calcification and osteochondrogenic phenotype
change in vitro.67–69 No calcification occurs in human SMCs
cultured in a medium containing 1.4 mM phosphate, but
calcification is induced in a dose- and time-dependent manner
when phosphate levels are increased from 1.6 to 3.0 mM. The
finding that elevated phosphate induces SMC calcification was
confirmed by other investigators.68,70 In addition to SMC cultures,
rat aortas cultured in elevated phosphate medium undergo
medial calcification.71 Together, these studies demonstrate that
elevated phosphate is a strong inducer of vascular calcification.
Phosphate transport into cells is primarily mediated by
sodium-dependent phosphate cotransporters, and three types
of cotransporters have been identified based on structure,
tissue expression and biochemical characteristics.72,73 The
type I and type II sodium-dependent phosphate cotranspor-
ters are primarily expressed in kidney and intestinal
epithelium, and their functions are important for the
maintenance of phosphate homeostasis in body.72,73 The
type III sodium-dependent phosphate cotransporters, Pit-1
and Pit-2, were originally identified as cell-surface receptors
for the gibbon ape leukemia virus and the amphotropic
murine retrovirus, respectively. Type III members are widely
expressed in tissues such as kidney, liver, lung, heart, brain,
osteoblast, chondrocyte, and SMCs.67,74–79
A functional sodium-dependent phosphate transport
system has been characterized in vascular SMCs.67,79,80
Failed anticalcific
processes
a. Loss of inhibitors
(cMGP, pOPN,
fetuin, pyrophosphate)
b. Defective osteoclastogenesis
phosphate
Elastolysis
MMPs
Vascular calcification
Initiation and/or progression
Phosphate
Calcium
Lipids
Inflammation
Cytokines/hormones
Uremic serum
Osteochondrogenic
differentation of
vascular cells; Ca/Pi
loaded matrix vesicles
Matrix degradation
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Remodeling
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Phosphate
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Apoptosis
Apoptotic bodies
Circulating nucleation
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Figure 1 | Major mechanisms of vascular calcification. Six different mechanisms that have been proposed to regulate the initiation
or progression of vascular calcification are illustrated, along with key molecular mediators where known. The extent to which each of these
mechanisms plays a role in vascular calcification in various disease states, including hyperphosphatemia and ESRD, is currently unknown.
cMGP; gamma carboxylated matrix gla protein, pOPN; phosphorylated osteopontin.
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RT-PCR revealed expression of type III sodium-dependent
phosphate cotransporters, Pit-1 and Pit-2, in vascular SMCs,
whereas no transcripts for type I and type II sodium-
dependent phosphate cotransporters were detected. Real-
time PCR indicated that Pit-1 mRNA levels were higher than
Pit-2 levels in SMC.79 Treatment of vascular SMCs with a
competitive inhibitor of sodium-dependent phosphate co-
transporters, phosphonoformic acid, caused a dose-depen-
dent inhibition of phosphate uptake, calcification, and
osteochondrogenic phenotype in SMCs.67,68,70 These results
suggested that phosphate transporter activity was necessary
for mineralization as well as osteochondrogenic transition in
human SMCs.
As phosphonoformic acid has lower affinity for type III
than type II receptors,80 the requirement of phosphate uptake
for SMC calcification was further examined using SMCs that
were stably transduced with a Pit-1-specific small hairpin
RNA.79 Pit-1 small hairpin RNA-expressing cells had reduced
Pit-1 mRNA and protein levels as determined by Northern
and Western blots, respectively. Sodium-dependent phos-
phate uptake in the cells was reduced compared with that in
control cells. After incubation with elevated phosphate for 7,
10 or 14 days, there was substantially reduced calcification in
Pit-1 knockdown cells compared to control cells. Of interest,
restoration of phosphate uptake in Pit-1 knockdown cells by
overexpression of mouse Pit-1 rescued elevated phosphate-
induced mineralization. Similar to phosphonoformic acid,
inhibition of phosphate uptake by Pit-1 small hairpin RNA
blocked the expression of phosphate-induced osteogenic
differentiation markers, Runx2 and osteopontin. Further-
more, we determined that neither phosphate loading of
matrix vesicles nor cell death was mediated by Pit-1 in SMC.
These studies indicated that sodium-dependent phosphate
cotransporters, in particular Pit-1, might be a major
mechanism for controlling vascular calcification and SMC
phenotypic state. Taken together, these results demonstrate
that phosphate transport through Pit-1 is required for
calcification of human SMC in vitro. A model for the
possible functions of elevated phosphate and Pit-1 in SMC
calcification is shown in Figure 2.
Recent studies have supported a role for increased
phosphate uptake through Pit-1 in vascular calcification
in vivo. Mizobuchi et al.81 showed that mRNA levels of Pit-1
and Runx2 were increased in calcified aorta of uremic rats
with severe hyperparathyroidism, whereas no increase was
observed in non-calcified aorta of control animals. Likewise,
LDLR/ mice fed a high-fat diet showed elevated levels of
serum tumor necrosis factor a and Pit-1 in calcified aortas.
In vitro, several factors that have been shown to induce
vascular calcification also induce Pit-1 in SMCs. Long-term
treatment of human SMCs with elevated calcium levels leads
to increased Pit-1 mRNA levels, phosphate uptake, and
calcification.82 Likewise, PDGF promotes calcification in
cultured SMCs and strongly induces Pit-1 expression.75,83 In
addition, bone morphogenetic protein 2 (BMP-2), a potent
osteogenic protein, has been shown to promote vascular
calcification36,84,85 and BMP-2 increased phosphate uptake in
human SMC in a time- and dose-dependent manner.86
Finally, transglutaminase (TG) appears to be an important
regulator of endogenous expression, as Pit1 levels were
observed in TGþ /þ SMCs but absent in TG/ SMCs in
the presence or absence of elevated phosphate.87 Whether
Pit-1 plays a role in vascular calcification in human disease is
not yet known, but it is of interest that a single nucleotide
polymorphism that was significantly associated with left
ventricular mass index and relative wall thickness in
hypertensive black siblings was identified in the Pit-1 gene
(SLC20A1_cv9546580). The functional significance of this
SNP is not yet clear as it occurs in the intronic region of the
gene, but its association with outcomes that are thought to be
impacted by vascular calcification is provocative.88
It is becoming increasingly clear that vascular calcification
shares a number of similarities with osteogenesis and bone
mineralization, and indeed, phosphate transport through
Pit-1 has been recently implicated in regulation of bone
formation and mineralization. Pit-1 mRNA levels increase
during osteoblast differentiation and are correlated with
mineralization.89 Additionally, in situ hybridization in
developing embryonic murine metatarsals showed that Pit-
1 expression was first detected in 17-day-old embryos at a
stage when the chondrocytes undergo hypertrophy and
initiate mineralization. Moreover, Pit-1 expression was
restricted to a subset of hypertrophic chondrocytes where
matrix mineralization occurs.90 In osteoblast-like cells,
epinephrine, insulin-like growth factor 1, platelet-derived
growth factor, and BMP2 have been shown to upregulate
Pit-1,77,91–93 when transforming growth factor b and inter-
leukin 8 induce Pit-1 in chondrogenic cells94,95 Importantly,
Elevated phosphate BMP,
PDGF,
Ca
Runx2
AP ?
Alkaline
phosphatase
Osteocalcin,
osteopontin
Collagen
Ca/P
loaded
matrix
vesicles
SMC genes
Pit-1
?
Pi
Figure 2 | Proposed role of elevated phosphate (Pi) in
osteochondrogenic phenotype change and matrix
mineralization in vascular SMC. Pi enters the cell through the
sodium-dependent phosphate cotransporter, Pit-1, and induces
an osteochondrogenic phenotype change. This stimulates matrix
vesicle calcium and Pi loading, as well as matrix changes that
promote calcification. Molecules involved in regulating Pi loading
of matrix vesicles or Pi efflux are currently unknown.
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as in SMC, inhibition of Pit-1 in osteoblasts blocked
mineralization in vitro 93,96 and in vivo.96 Thus, it is likely
that phosphate transport through Pit-1 is a common
requirement for cell-mediated biomineralization.
CONCLUSIONS
Vascular calcification is a major contributor to CVD in ESRD
patients. Susceptibility to vascular calcification is genetically
determined and involves a growing number of inducers and
inhibitors. Hyperphosphatemia promotes vascular calcifica-
tion in part by promoting SMCs to undergo an osteochon-
drogenic phenotype change through a mechanism requiring
sodium-dependent phosphate cotransporters. Upregulation
of sodium-dependent phosphate cotransporters in SMCs by
disease state and cytokines may facilitate vascular calcifica-
tion even when serum phosphate levels are in the normal
range.
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